<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="ijerph-17-04951-t001" orientation="portrait" position="float">
 <object-id pub-id-type="pii">ijerph-17-04951-t001_Table 1</object-id>
 <label>Table 1</label>
 <caption>
  <p>Summary of studies on HCV reinfection in low- and middle-income countries.</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"> </th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Author, Year</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study Design</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Setting
     <break/>(LMICs in Multi-Site Studies, SES and Median Income of Relevant Countries)
    </th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study Population (N)
     <break/>% Male
     <break/>Initial HCV Prevalence
    </th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Testing Interval</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reinfection Rate (per 100 PY)
     <break/>(Available Rates among Relevant Special Populations Noted)
    </th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Measurement of Reinfection</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Follow-Up Time
     <break/>(Participant Range if Given)
    </th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Attrition Rate (Loss to Follow-Up)</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Foster et al., 2019 [
     <xref rid="B20-ijerph-17-04951" ref-type="bibr">20</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Integrated analysis of clinical trials</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multi-country
     <break/>Upper middle-income
     <break/>(Mexico = $9673
     <break/>Romania = $12,306
     <break/>Russia = $11,288)
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N = 1819
     <break/>Male 57.0%
     <break/>Prevalence = 50.0% *
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Followed for 24 weeks, reinfection detected at week 12</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.6 </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Deep gene sequencing</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24 weeks</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.01</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Huang et al., 2019 [
     <xref rid="B21-ijerph-17-04951" ref-type="bibr">21</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cohort study</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Taiwan = $14,273
     <break/>Upper middle-income
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N = 219
     <break/>Male 100.0%
     <break/>Prevalence = 33.7%
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Varied: either 12 months (majority), following abnormal labs (minority)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.5
     <break/>14.1
     <break/>(for DAA treatment recipients)
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No differentiation between reinfection and relapse</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.1–6.6 years</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.04</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Latham et al., 2019 [
     <xref rid="B22-ijerph-17-04951" ref-type="bibr">22</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Systematic review and meta-analysis</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multi-country
     <break/>Upper middle-income
     <break/>(Georgia = $4722)
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N = 827
     <break/>Sex not delineated
     <break/>Prevalence not delineated
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Varied among studies</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.9
     <break/>(for recent PWID)
     <break/>0.6
     <break/>(for OST recipients)
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Genotyping, deep gene sequencing or none</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24 weeks–3 years</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.02</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rahman et al., 2019 [
     <xref rid="B23-ijerph-17-04951" ref-type="bibr">23</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prospective cohort</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bangladesh = $1698
     <break/>Lower middle-income
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N = 200
     <break/>Sex not delineated
     <break/>Prevalence = 42%
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Once 12 weeks after SVR</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.2</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Genotyping</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12 weeks</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.05</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reddy et al., 2018 [
     <xref rid="B24-ijerph-17-04951" ref-type="bibr">24</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cohort study</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multi-Country
     <break/>Upper middle-income
     <break/>(Brazil = $9001,
     <break/>Argentina = $11,683,
     <break/>Mexico = $9673,
     <break/>Taiwan = $14,273)
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N = 1503
     <break/>Male 60%
     <break/>Prevalence = 56.8% *
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day 1, week 24, 48, 96 and 144</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.02</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reflex genotyping</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">144 weeks</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.01</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rockstroh et al., 2017 [
     <xref rid="B25-ijerph-17-04951" ref-type="bibr">25</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical trial</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multi-Country
     <break/>Upper middle-income
     <break/>(Russia = $11,288)
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N = 228
     <break/>Male 80%Prevalence = 50% *
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not delineated</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.9</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Deep gene sequencing</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12 weeks</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.02</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sarrazin et al., 2017 [
     <xref rid="B26-ijerph-17-04951" ref-type="bibr">26</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cohort Study</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multi-Country
     <break/>Upper middle-income
     <break/>(Russia = $11,288)
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N = 3004
     <break/>Sex not delineated
     <break/>Prevalence = 50% *
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Once at 24 weeks</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.5</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Deep gene sequencing </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24 weeks</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not delineated</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>
    <bold>*</bold> background prevalence average among all sites in multi-site studies.
   </p>
  </fn>
 </table-wrap-foot>
</table-wrap>
